Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans
M. Del Poeta et al., Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans, ANTIM AG CH, 44(3), 2000, pp. 739-746
Cryptococcus neoformans is an opportunistic fungal pathogen that causes lif
e-threatening infections of the central nervous system. Existing therapies
include amphotericin B, fluconazole, and flucytosine, which are limited by
toxic side effects and the emergence of drug resistance. We recently demons
trated that the protein phosphatase calcineurin is required for growth at 3
7 degrees C and virulence of C. neoformans, Because calcineurin is the targ
et of potent inhibitors in widespread clinical use, cyclosporine and FK506
(tacrolimus), it is an attractive drug target for novel antifungal agents.
Here we have explored the synergistic potential of combining the calcineuri
n inhibitor FK506 or its nonimmunosuppressive analog, L-685,818, with other
antifungal agents and examined the molecular basis of FK506 action by usin
g genetically engineered fungal strains that lack the FK506 target proteins
FKBP12 and calcineurin, We demonstrate that FK506 exhibits marked synergis
tic activity with the H(+)ATPase inhibitor bafilomycin A(1) via a novel act
ion distinct from calcineurin loss of function. FK506 also exhibits synergi
stic activity with the pneumocandin MK-0991/caspofungin acetate (formerly L
-743,873), which targets the essential beta-1,3 glucan synthase, and in thi
s case, FK506 action is mediated via FKBP12-dependent inhibition of calcine
urin. Finally, we demonstrate that FK506 and fluconazole have synergistic a
ctivity that is independent of both FKBP12 and calcineurin and may involve
the known ability of FK506 to inhibit multidrug resistance pumps, which are
known to export azoles from fungal cells. In summary, our studies illustra
te the potential for synergistic activity of a variety of different drug co
mbinations and the power of molecular genetics to define the mechanisms of
drug action, as well as identify a novel action of FK506 that could have pr
ofound implications for therapeutic or toxic effects in other organisms, in
cluding humans.